Articles
-
Federal 340B Drug Pricing Policies Need Reform to Realize Potential
USC Schaeffer study finds Federal 340B Drug Pricing Program oversight needs tightening to ensure discounts reach the right safety-net providers and patients
Categorized in -
The Hidden Cost of Covid-19: Years of Life Lost Among the Young
The focus on deaths affecting mainly the elderly is unfortunate because it likely created a false sense of security among the young.
Categorized in -
Biosimilars Competition Helps Patients More Than Generic Competition
Well-intended proposals to have the government intervene and “incentivize” biosimilar uptake may result in less price competition, not more.
Categorized in -
Two Decades Later, Uptake of Less Invasive Valve Replacement for Heart Disease Remains Low Despite Billions in Social Value
The USC Schaeffer white paper illustrates procedure’s benefits for older Americans yet uptake remains low.
Categorized in -
Federal Government Should Advise on Drug Negotiations, Not Run Them
Schaeffer Center experts Karen Mulligan and Darius Lakdawalla argue that the Department of Health and Human Services should help advice drug price negotiations instead of running them.
Categorized in -
Study Finds More Than 9 Million Excess Life Years Lost During COVID Pandemic
Black and Hispanic persons have experienced a disproportionate number of life-years lost.
Categorized in -
Money for the Infrastructure Bill is Coming at the Expense of Medicare Part D
The $1 trillion infrastructure bill will leave a lot of chronically ill people by the side of the road.
Categorized in -
Deaths Tied to Opioids Rose Among Less-Educated Whites Following LA County’s Stay-At-Home Order
Opioid-related deaths among Blacks, Asians and Latinos dropped during the same period.
Categorized in -
Opioid Overdose Risk Appears Higher in Older Americans, USC Study Indicates
One in 10 adults were at risk of overdose, with older Americans relying on high doses of opioids more than younger adults, researchers found in a national sample of prescription claims.
Categorized in -
After Their Initial Diagnosis, Many Adult COVID-19 Patients Continue Seeking Medical Care for up to Six Months or More
Analyzing claims data, does COVID-19 related healthcare utilization persist in for 180 days or more, also known as long COVID, after their initial diagnosis?
Categorized in